Home > Insider Trading > Filing (0001209191-14-003013)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1009356	Salix Pharmaceuticals Ltd	SLXP	Pharmaceutical Preparations (2834)	943267443

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1212669	C Adam Derbyshire	8510 Colonnade Center Drive Raleigh NC 27615	Evp Finance/Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-01-09	30,001	$18.87	209,396	No	4	M	Direct
Common Stock	Disposition	2014-01-09	2,400	$91.95	206,996	No	4	S	Direct
Common Stock	Disposition	2014-01-09	27,601	$91.44	179,395	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Buy Common Stock	Disposition	2014-01-09	30,001	$0.00	30,001	$18.87

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2014-06-17	No	4	M	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Option to Buy Common Stock	$17.63		2015-06-09	20,000	20,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2015-06-09	20,000	20,000	Direct

Footnotes

The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2013.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.91 to $92.03, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.91 to $91.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Options are 100% vested.
The reporting person's prior Forms 4 mistakenly indicated the total number of derivative securities beneficially owned was 30,000 when in fact the total number of derivative securities beneficially owned is 30,001. The reporting person's transactions and derivative security holdings reported herein reflect the correct information as of the date hereof.